In patient-derived murine models of RAS-mutated rhabdomyosarcoma, the MEK inhibitor trametinib results in a modest reduction in tumour growth, which is further enhanced when combined with the synergistic IGF1-R inhibitor gatinutmab [177]. Here, IGF1R is linked to rhabdomyosarcoma.